Circulating mitochondrial biomarkers for drug-induced liver injury-Reference-Cited by-同舟云学术

Circulating mitochondrial biomarkers for drug-induced liver injury

Published:2015-11 Issue:11 Volume:9 Page:1215-1223
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Shi Qiang¹,Yang Xi¹,Mattes William B¹,Mendrick Donna L²,Harrill Alison H³,Beger Richard D¹

Affiliation:

1. Division of Systems Biology, National Center for Toxicological Research, Food & Drug Administration, 3900 NCTR Road, Jefferson, AR 72079, USA

2. Regulatory Activities, National Center for Toxicological Research, Food & Drug Administration, 3900 NCTR Road, Jefferson, AR 72079, USA

3. Department of Environmental & Occupational Health, The University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA

Abstract

Liver mitochondria affected by drugs can be released into circulation and serve as biomarkers for drug-induced liver injury (DILI). The tissue specificity of ALT was improved by differentiating cytosolic ALT1 and mitochondrial ALT2 isoforms released in circulation. Prior to ALT elevation, mitochondrial cytochrome c, OCT, GLDH, CPS1 and DNA were increased in circulation following DILI. The baseline expression of mt-Nd6 was predictive of individual DILI susceptibility in animals. As mitochondrial DILI biomarkers appeared to be drug or species dependent, they might have value in clinical scenarios when culprit drugs are established, but may not be ideal tools to assess DILI potentials of new drugs.

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm.15.59

Reference51 articles.

1. FDA. New molecular entity and new therapeutic biological product approvals for 2014 (2015). www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm429247.htm.

2. FDA. New molecular entity and new therapeutic biological product approvals for 2015 (2015). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm430302.htm.

3. FDA. Guidance for industry drug-induced liver injury: premarketing clinical evaluation (2009). http://www.fda.gov/downloads/Drugs/./Guidances/UCM174090.pdf.

4. Mitochondrial Involvement in Drug-Induced Liver Injury

5. Prediction of Liver Injury Induced by Chemicals in Human With a Multiparametric Assay on Isolated Mouse Liver Mitochondria

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Environmental and Genetic Determinants of Ankylosing Spondylitis;International Journal of Molecular Sciences;2024-07-17

2. Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity;Drug Metabolism and Disposition;2024-01-29

3. The role of mitochondria in rheumatic diseases;Nature Reviews Rheumatology;2022-09-29

4. Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury via mitochondrial or other mechanisms;Acta Pharmaceutica Sinica B;2021-12

5. Mechanistic identification of biofluid metabolite changes as markers of acetaminophen-induced liver toxicity in rats;Toxicology and Applied Pharmacology;2019-06